Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity
vivani | April 15, 2025
Read More
Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
vivani | March 31, 2025
Read More
Vivani Medical Announces $8.25M Private Placement Equity Financing
vivani | March 27, 2025
Read More
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
vivani | April 4, 2023
Read More
Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
vivani | March 31, 2023
Read More
Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division
vivani | March 21, 2023
Read More
Vivani Medical to Present at the ThinkEquity Investor Conference
vivani | November 14, 2022
Read More
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates
vivani | November 14, 2022
Read More
Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)
vivani | August 31, 2022
Read More
Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.
vivani | August 30, 2022
Read More
Blog Navigation
Contact Us
To learn more about Vivani, and to learn more about our strategic focus on NPM-139 (semaglutide implant), please fill out this form.